Rafferty Asset Management
CRNX

Rafferty Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Rafferty Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+5,787
New +$215K ﹤0.01% 1083
2026
Q1 		– Sell
-4,865
Closed -$226K – 1081
2025
Q4 		$226K Sell
4,865
-1,314
-21% -$58.5K ﹤0.01% 1065
2025
Q3 		$257K Sell
6,179
-84,577
-93% -$2.7M ﹤0.01% 1019
2025
Q2 		$2.61M Sell
90,756
-11,375
-11% -$351K 0.01% 542
2025
Q1 		$3.43M Buy
102,131
+20,874
+26% +$780K 0.01% 447
2024
Q4 		$4.15M Sell
81,257
-16,193
-17% -$906K 0.01% 451
2024
Q3 		$4.98M Sell
97,450
-14,719
-13% -$759K 0.02% 427
2024
Q2 		$5.02M Sell
112,169
-104,680
-48% -$4.83M 0.02% 414
2024
Q1 		$10.2M Sell
216,849
-27,440
-11% -$1.07M 0.04% 261
2023
Q4 		$8.69M Buy
244,289
+46,548
+24% +$1.43M 0.04% 317
2023
Q3 		$5.88M Buy
197,741
+59,555
+43% +$1.23M 0.03% 356
2023
Q2 		$2.49M Buy
138,186
+9,478
+7% +$189K 0.01% 586
2023
Q1 		$2.07M Buy
128,708
+22,210
+21% +$411K 0.01% 604
2022
Q4 		$1.95M Buy
106,498
+31,045
+41% +$547K 0.02% 586
2022
Q3 		$1.48M Buy
75,453
+30,684
+69% +$626K 0.02% 576
2022
Q2 		$835K Sell
44,769
-33,366
-43% -$666K 0.01% 704
2022
Q1 		$1.72M Buy
78,135
+26,023
+50% +$527K 0.01% 654
2021
Q4 		$1.48M Buy
52,112
+24,599
+89% +$606K 0.01% 761
2021
Q3 		$579K Buy
+27,513
New +$576K ﹤0.01% 1009

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's CRNX Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 5,787 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #1083 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in CRNX as recently as Q4 2025.

Rafferty Asset Management first reported a position in CRNX in Q3 2021 and has held it in 19 quarters since. The position peaked at $10.2M in Q1 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Rafferty Asset Management held 5,787 shares of Crinetics Pharmaceuticals worth $217K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Rafferty Asset Management position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1083 holding.
  • Rafferty Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Rafferty Asset Management's Crinetics Pharmaceuticals position peaked at $10.2M in Q1 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.